Tumor immunotherapy pharmaceutical composition and application thereof

Through the combined use of cannabidiol and canagliflozin in tumor immunotherapy drug composition, the expression of PD-L1 on the surface of tumor cells was inhibited, and the side effects of existing antibody treatments were solved, which significantly improved the anti-tumor effect, and through card The combination of gliflozin and vitamin E enhances T cell activity and achieves safer and more effective tumor immunotherapy.

CN118986967APending Publication Date: 2024-11-22SHANGHAI HUI TIAN JIN ZE BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411137280.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing anti-PD-1/PD-L1 antibody immunotherapy has problems of major side effects and limited application, and it is necessary to develop safer and more effective tumor immunotherapy drugs.

Method used

Provided is a tumor immunotherapy pharmaceutical composition, comprising cannabidiol and canagliflozin, and a combination of canagliflozin and vitamin E, to block PD-1/PD by inhibiting the expression of PD-L1 protein on the surface of tumor cells. -L1 signaling pathway enhances the killing ability of T cells to tumor cells.

Benefits of technology

The combination of cannabidiol and canagliflozin significantly improved the anti-tumor effect. The combination of canagliflozin and vitamin E further improved the number and activity of T cells, significantly enhanced the anti-tumor effect of the drug, and avoided the normal tissues. Injury, reducing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986967A_ABST
    Figure CN118986967A_ABST
Patent Text Reader

Abstract

The invention discloses a tumor immunotherapy pharmaceutical composition and application thereof. The pharmaceutical composition comprises cannabidiol and canagliflozin, and experiments prove that the combined use of cannabidiol and canagliflozin can play a synergistic role, so that the anti-tumor effect is remarkably improved; or the pharmaceutical composition comprises canagliflozin, vitamin E and optional cannabidiol, and canagliflozin and cannabidiol can effectively inhibit expression of PD-L1 on the surfaces of tumor cells and relieve the inhibition degree of T cell activation; the added vitamin E can further improve the number and activity of T cells and significantly enhance the killing ability of the T cells after immunosuppression is relieved, and the two aspects cooperate and supplement each other to significantly improve the anti-tumor effect of the medicine. The cannabidiol and the canagliflozin in the medicine directly act on PD-L1 on the surfaces of tumor cells, so that the medicine is more targeted, damage of T cells to normal tissues is not easily caused, and side effects are avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine, and in particular to a tumor immunotherapy drug composition and application thereof. Background Art

[0002] In recent years, with the in-depth research and development of tumor immunology, cancer immunotherapy (CIT) has become an important means of treating various types of tumors, and has achieved significant therapeutic effects in clinical practice, bringing new hope to cancer patients.

[0003] In tumor immunotherapy, the targeted treatment strategy of immune checkpoint PD-1 / PD-L1 is particularly eye-catching. PD-1, or programmed cell death protein 1, is an immunosuppressive molecule widely expressed on the surface of activated T cells. As a ligand of PD-1, PD-L1 (programmed death ligand 1) is expressed at a low level in normal tissues, but its expression level is significantly increased in a variety of tumor tissues. The binding of PD-1 to PD-L1 triggers the immunosuppressive signal of T cells, resulting in the obstruction of T cell activation and the inability to effectively kill tumor cells, thereby allowing tumor cells to escape immune system. Blocking the interaction between PD-1 and PD-L1 can reactivate tumor-specific T cells and restore their killing function against tumor cells. This strategy has become an effective means of tumor immunotherapy. At present, there are a variety of monoclonal antibody drugs targeting PD-1 / PD-L1 on the market, which have shown good efficacy in the treatment of solid tumors such as melanoma, renal cancer and non-small cell lung cancer.

[0004] However, although antibody therapy has been successful in some patients, its wide range of side effects limits its application in more patients. Therefore, the development of safer and more effective tumor immunotherapy drugs is an important research direction in this field. Summary of the invention

[0005] In view of the problems of large side effects and limited application of existing anti-PD-1 / PD-L1 antibody immunotherapy, the present invention provides a new tumor immunotherapy pharmaceutical composition and its application. The tumor immunotherapy pharmaceutical composition can inhibit the expression of PD-L1 protein on the surface of tumor cells, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the effect of T cells in killing tumor cells.

[0006] In order to solve the above technical problems, the present invention first provides a tumor immunotherapy pharmaceutical composition, which comprises: cannabidiol and canagliflozin.

[0007] Preferably, in the pharmaceutical composition, the mass dosage ratio of cannabidiol and canagliflozin is: (20-500): (1-100).

[0008] Another aspect of the present invention provides a tumor immunotherapy pharmaceutical composition, which comprises: canagliflozin and vitamin E.

[0009] Preferably, the pharmaceutical composition also includes cannabidiol.

[0010] Preferably, in the pharmaceutical composition, the mass dosage ratio of cannabidiol, canagliflozin and vitamin E is: (20-500): (1-100): (10-400).

[0011] Preferably, the pharmaceutical composition further comprises: at least one of a pharmaceutically acceptable carrier, an excipient, a wetting agent, an emulsifier, and a pH buffer.

[0012] Preferably, the dosage form of the pharmaceutical composition comprises at least one of oil, granules, tablets, powders, capsules, microcapsules, pills, powders, oral liquids, sols, sprays, and atomizers.

[0013] On the other hand, the invention also provides the use of the aforementioned tumor immunotherapy drug composition in the preparation of anti-tumor drugs.

[0014] Preferably, the tumor includes any one of colorectal cancer, lung cancer, liver cancer, gastric cancer, bladder cancer, esophageal cancer, breast cancer, and melanoma.

[0015] Compared with the prior art, the beneficial effects of the present invention include at least:

[0016] (1) The present invention provides a tumor immunotherapy drug composition, which comprises cannabidiol and canagliflozin. Experiments have shown that compared with the use of cannabidiol or canagliflozin alone, the combined use of cannabidiol and canagliflozin can exert a synergistic effect and significantly improve the anti-tumor effect.

[0017] (2) Another tumor immunotherapy drug composition provided by the present invention comprises: canagliflozin and vitamin E, and optionally cannabidiol, wherein canagliflozin and cannabidiol can effectively inhibit the expression of PD-L1 on the surface of tumor cells, alleviate the degree of inhibition of T cell activation, and especially avoid the subsequent inhibition of activation of newborn T cells; at the same time, the added vitamin E can further increase the number and activity of T cells, and significantly enhance the killing ability of T cells after the release of immunosuppression. The two aspects cooperate and complement each other, significantly improving the anti-tumor effect of the drug.

[0018] (3) Compared with anti-PD-1 / PD-L1 antibody immunotherapy, the cannabidiol and canagliflozin in the drug of the present invention directly act on PD-L1 on the surface of tumor cells, which is more targeted and less likely to cause T cells to damage normal tissues, thus avoiding the occurrence of side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Comparison of the anti-tumor effects of different drug compositions on mice with colorectal cancer, including:

[0020] A is the tumor tissue photos of mice in each group;

[0021] B is the weight growth curve of mice in each group;

[0022] C is the growth curve of the tumor volume of mice in each group;

[0023] D is the tumor weight of mice in each group.

[0024] Figure 2 Comparison of cell survival rates of different types of tumor cells after co-treatment with different drug compositions and Jurkat cells, where:

[0025] A is the comparison of the survival rate of RKO cells by CBD and CAG;

[0026] B is the comparison of the survival rate of H1975 cells by CBD and CAG;

[0027] C is the comparison of the survival rate of HepG2 cells by CBD and CAG;

[0028] D is the comparison of the survival rates of MGC803 cells between CBD and CAG.

[0029] Figure 3 Comparison of cell survival rates of different types of tumor cells after co-treatment with different drug compositions and Jurkat cells, where:

[0030] A is the comparison of the survival rate of T24 cells by CBD and CAG;

[0031] B is the comparison of the survival rate of TE-5 cells by CBD and CAG;

[0032] C is the comparison of the survival rate of MCF-7 cells by CBD and CAG;

[0033] D is the comparison of the survival rates of B16-F10 cells between CBD and CAG. DETAILED DESCRIPTION

[0034] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments.

[0035] As described in the background technology, existing anti-PD-1 / PD-L1 antibody immunotherapy has problems of large side effects and limited application. Therefore, the development of safer and more effective tumor immunotherapy drugs is an important research direction in this field.

[0036] Cannabidiol (CBD) is one of the cannabis extracts and has been widely developed for use in medical skin care products, beverages or foods with mood-improving functions, etc. In previous studies of the present invention, it was found that CBD can effectively reduce the expression of PD-L1 in tumors and can be applied to tumor immunotherapy.

[0037] Canagliflozin (CAG) is a selective inhibitor of the glucose co-transporter SGLT2 and an oral drug for the treatment of diabetes. The present invention has been experimentally proven to also show the effect of reducing the expression of PD-L1 in tumor cells, so canagliflozin can also be used as a candidate drug for negatively regulating the expression of PD-L1 in tumor cells.

[0038] Vitamin E is an important antioxidant, but it is also an effective immunomodulator that can promote the development of the body's immune organs and the differentiation of immune cells, and improve the body's cellular immunity and humoral immunity.

[0039] Based on the above research findings, the present invention first designs and provides a tumor immunotherapy drug composition, which comprises: CBD and CAG. CBD and CAG are used in combination in the hope that the drug composition can synergistically inhibit the expression of PD-L1, thereby improving the tumor immunotherapy effect of the drug.

[0040] In some embodiments, in the pharmaceutical composition, the mass ratio of CBD to CAG is: (20-500): (1-100).

[0041] The present invention also provides another tumor immunotherapy pharmaceutical composition, which contains CAG and vitamin E. On the one hand, CAG can reduce the expression of PD-L1 on the surface of tumor cells, alleviate the degree of inhibition of T cell activation, and avoid the subsequent inhibition of activation of newborn T cells, which leads to the fact that the effect of vitamin E in increasing the number and activity of T cells is not effectively or maximized; on the other hand, the added vitamin E is not only used to promote T cell proliferation and differentiation, increase the number and activity of T cells, but also can enhance the effect of T cells killing tumor cells after immunosuppression is relieved. The two cooperate with each other, complement each other, exert synergistic effects, and ultimately significantly improve the effect of immunotherapy.

[0042] In some embodiments, the pharmaceutical composition further comprises CBD.

[0043] In some embodiments, in the pharmaceutical composition, the mass ratio of CBD, CAG and vitamin E is: (20-500): (1-100): (10-400).

[0044] In some embodiments, the pharmaceutical composition further comprises: a pharmaceutically acceptable carrier, an excipient, a wetting agent, an emulsifier, and a pH buffer.

[0045] Suitable pharmaceutically acceptable carriers are well known to those of ordinary skill in the art. A full description of pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences. In the composition, the pharmaceutically acceptable carrier may contain a liquid such as water, phosphate buffer, Ringer solution, physiological saline, balanced salt solution, glycerol or sorbitol, etc. In addition, auxiliary substances such as lubricants, glidants, wetting agents or emulsifiers, pH buffer substances and stabilizers such as albumin, etc. may also be present in these carriers. When used, a safe and effective amount of the anti-tumor drug of the present invention is applied to a mammal (such as a human). Of course, the specific dose should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill range of a skilled physician. The exact effective amount for a subject depends on the size and health status of the subject, the nature and extent of the disease, and the therapeutic agent and / or combination of therapeutic agents selected for administration. For a given condition, the effective amount can be determined by routine experiments, and clinicians are able to judge it.

[0046] In some embodiments, the dosage form of the pharmaceutical composition includes oil, granules, tablets, powders, capsules, pills, powders, oral liquids, sols, sprays, atomizers, etc.

[0047] Another aspect of the present invention also provides the use of the above-mentioned tumor immunotherapy drug composition in the preparation of anti-tumor drugs.

[0048] In some embodiments, the tumor comprises any one of colorectal cancer, lung cancer, liver cancer, gastric cancer, bladder cancer, esophageal cancer, breast cancer, and melanoma.

[0049] The experimental process and experimental results of the present invention are described in detail below in conjunction with the accompanying drawings and embodiments.

[0050] The experimental methods used in the following examples were all carried out according to conventional conditions or conditions recommended by the manufacturers unless otherwise specified.

[0051] The materials and reagents used in the following examples, unless otherwise specified, can be obtained from commercial sources. Among them, cannabidiol was purchased from Yuxi Hongbao Biotechnology Co., Ltd.; canagliflozin was purchased from Xi'an Janssen Pharmaceutical Co., Ltd.; vitamin E was purchased from Zhejiang Xinhecheng Co., Ltd.; Anti-PD-1 was purchased from Bioxcell (Ultra-LEAF TM Purified anti-mouse CD279 (PD-1, BE0146); corn oil was purchased from Golden Sun Grain and Oil Company.

[0052] Example 1 In vivo antitumor effects of different pharmaceutical compositions

[0053] (I) Experimental process

[0054] Colorectal cancer cells MC38 were inoculated into 6-week-old female C57BL / 6 mice (1×10 6 The subcutaneous tumor model was established in vivo with 10 cells / mouse. The tumor volume reached 50 mm 3 Afterwards, the mice were grouped and administered the following drug combinations: (1) control group (no administration), (2) anti-PD-1 (100 μg / each time) group, (3) vitamin E (50 mg / kg) group, (4) CBD (100 mg / kg) group, (5) CBD (100 mg / kg) + vitamin E (50 mg / kg) group, (6) CAG (20 mg / kg) group, (7) CAG (20 mg / kg) + vitamin E (50 mg / kg) group, (8) CBD (100 mg / kg) + CAG (20 mg / kg) group, and (9) CBD (100 mg / kg) + CAG (20 mg / kg) + vitamin E (50 mg / kg) group.

[0055] The tumor weight, volume and body weight of mice were monitored every 2 days. The tumor volume calculation formula is: tumor volume (mm 3 )=0.5×(length)×(width) 2 The mice were killed 14 days after administration and the tumors were dissected.

[0056] The dissolution method of the drug composition is: 10% DMSO + corn oil, 100 μL / mouse by intragastric administration, and the mice in the control group are injected with an equal volume of the same solvent.

[0057] (II) Experimental results

[0058] like Figure 1As shown in Figures AD, the experimental results of the comparison groups (1)(2)(4)(6) show that the therapeutic effects of CBD and CAG are comparable, and both are comparable to the therapeutic effects of the commonly used anti-PD-1 antibodies. Further comparison of the experimental results of the comparison groups (4)(6)(8) shows that compared with the use of CBD or CAG alone, the immunotherapy effect is significantly improved when CBD+CAG is used in combination, showing a synergistic effect.

[0059] When vitamin E was added, the experimental results of the control group (1)(3)(6)(7) showed that compared with the use of CAG or vitamin E alone, the combined use of CAG and vitamin E had a better tumor inhibition effect and also had a synergistic effect.

[0060] Similarly, the experimental results of the comparison groups (1)(3)(4)(5) show that compared with the use of CBD or vitamin E alone, the combined use of CBD and vitamin E has a better tumor inhibition effect and a synergistic effect.

[0061] The experimental results of the comparison groups (1)(3)(8)(9) show that compared with the use of vitamin E and CBD+CAG alone, the combined use of CBD+CAG+vitamin E has a stronger inhibitory effect on tumor growth and has a synergistic effect.

[0062] The above results show that in the pharmaceutical composition provided by the present invention, when CBD and CAG are used in combination, a synergistic effect is exerted; in addition, when any one or both of CBD and CAG are used in combination with vitamin E, a synergistic effect is also exerted to produce a stronger anti-tumor effect.

[0063] Example 2 Different pharmaceutical compositions enhance the effect of T cells killing different types of tumor cells in vitro (I) Experimental process

[0064] Based on the research results of Example 1, several pharmaceutical compositions with better immunotherapy effects were added to different types of tumor cells together with T cells for culture to study the effects of different pharmaceutical compositions on enhancing T cells' killing of different types of tumor cells in vitro. The specific experimental process is as follows:

[0065] Colorectal cancer cells (RKO), lung cancer (H1975), liver cancer (HepG2), gastric cancer cells (MGC-803), bladder cancer cells (T24), esophageal cancer cells (TE-5), breast cancer cells (MCF-7) and melanoma cells (B16-F10) in logarithmic growth phase were cultured at 5×10 4The cells were inoculated at a density of 100 / mL in a 12-well plate and placed in a 37°C, 5% CO2 incubator for overnight growth. The supernatant was removed and CBD+vitamin E composition, CAG+vitamin E composition, CBD+CAG composition, and CBD+CAG+vitamin E composition were added respectively. A blank culture medium was set as a control group and incubated together for 12 hours. Jurkat cells (i.e., T cells) were added at a ratio of 1:500 and cultured for 24 hours. The supernatant was removed, and the cells were washed twice with PBS, and then 4% paraformaldehyde was added to fix the cells. After washing twice with PBS, crystal violet was added for staining for 30 minutes, and finally the excess crystal violet was washed with PBS, and the data was collected by taking pictures.

[0066] (II) Experimental results

[0067] like Figure 2 AD chart and Figure 3 As shown in the AD figure, compared with the control group, the four experimental groups (CBD+vitamin E composition, CAG+vitamin E composition, CBD+CAG+vitamin E composition) can significantly reduce the survival rate of colorectal cancer cells (RKO), lung cancer (H1975), liver cancer (HepG2), gastric cancer cells (MGC-803), bladder cancer cells (T24), esophageal cancer cells (TE-5), breast cancer (MCF-7) and melanoma (B16-F10), and induce apoptosis of tumor cells, indicating that these compositions can enhance the cytotoxicity of T cells to tumor cells by downregulating the expression of PD-L1 in tumor cells. Among them, the anti-tumor effects of the two compositions of CBD+CAG composition and CBD+CAG+vitamin E composition are more significant.

[0068] In summary, the present invention first provides a tumor immunotherapy pharmaceutical composition, which comprises: cannabidiol and canagliflozin, and experiments have shown that compared with the use of cannabidiol or canagliflozin alone, the combined use of cannabidiol and canagliflozin can exert a synergistic effect and significantly improve the anti-tumor effect. The present invention also provides another tumor immunotherapy pharmaceutical composition, which comprises: canagliflozin and vitamin E, and optionally cannabidiol, wherein canagliflozin and cannabidiol can effectively inhibit the expression of PD-L1 on the surface of tumor cells, alleviate the degree of inhibition of T cell activation, and especially avoid the subsequent activation of newborn T cells from being still inhibited; at the same time, the added vitamin E can further increase the number and activity of T cells, and significantly enhance the killing ability of T cells after the release of immunosuppression. The two aspects cooperate with each other and complement each other, significantly improving the anti-tumor effect of the drug.

[0069] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.

Claims

1. A tumor immunotherapy pharmaceutical composition, characterized in that: The pharmaceutical composition comprises cannabidiol and canagliflozin.

2. The tumor immunotherapy pharmaceutical composition according to claim 2, characterized in that: In the pharmaceutical composition, the mass dosage ratio of cannabidiol and canagliflozin is: (20-500): (1-100).

3. A tumor immunotherapy pharmaceutical composition, characterized in that: The anti-tumor drug composition comprises: canagliflozin and vitamin E.

4. The tumor immunotherapy pharmaceutical composition according to claim 3, characterized in that: The pharmaceutical composition also includes cannabidiol.

5. The tumor immunotherapy pharmaceutical composition according to claim 4, characterized in that: In the pharmaceutical composition, the mass ratio of cannabidiol, canagliflozin and vitamin E is: (20-500): (1~100):(10~400)。 6. The tumor immunotherapy pharmaceutical composition according to any one of claims 1 to 5, characterized in that: The pharmaceutical composition further comprises: at least one of a pharmaceutically acceptable carrier, an excipient, a wetting agent, an emulsifier, and a pH buffer.

7. The tumor immunotherapy pharmaceutical composition according to claim 6, characterized in that: The dosage form of the pharmaceutical composition comprises at least one of oil, granules, tablets, powders, capsules, microcapsule preparations, pills, powders, oral liquids, sols, sprays, and atomizers.

8. Use of the tumor immunotherapy drug composition according to any one of claims 1 to 5 in the preparation of anti-tumor drugs.

9. The use according to claim 8, characterized in that The tumor includes any one of colorectal cancer, lung cancer, liver cancer, gastric cancer, bladder cancer, esophageal cancer, breast cancer, and melanoma.